Health

Results: 265-276 of 6009

ICD 2025: New data demonstrate Nemluvio®’s (nemolizumab) favorable safety profile and sustained and clinically meaningful improvements in symptoms of prurigo nodularis up to two years

LabPMM® Receives New York State Approval for the NPM1 MRD Assay - Informing Therapy and Accelerating Targeted Trials

PR Newswire associated0

Genomics announces next stage of global roll-out of its predictive clinical tool Health Insights - the first ever UKCA-marked and MHRA registered test that combines genetic and clinical factors to predict and prevent common diseases

GlobeNewswire associated1

EarlyHealth Group Acquires Corena to Drive $100M Growth in Türkiye’s Life Sciences Sector

PR Newswire associated0

AtomVie Global Radiopharma and TerraPower Isotopes Announce Strategic Supply Agreement for Actinium-225 to Advance Radiopharmaceutical Development and Manufacturing

Sharjah to Host World Congress for Inclusion 2025 -- First Time in the Middle East and North African Region

PR Newswire associated0

GenBio AI Welcomes Emma Lundberg as Co-Founder and Chief Scientific Advisor

PR Newswire associated0

Endo Completes International Pharmaceuticals Business Divestiture

Celltrio Secures $15 Million Financial Investment to Accelerate Global Expansion in Cell Culturing and Cell & Gene Therapy Automation

Isomorphic Labs appoints Dr. Ben Wolf as Chief Medical Officer and establishes US Presence

Avata Biosciences Signs Co-Development and Licensing Agreement with Oceanus Bio for Exclusive Rights in Japan and Asia (Excluding China and India) for Novel Adult and Pediatric Oral Cannabidiol Therapies for Development in Epilepsy and Schizophrenia

Figure 1. Biocytogen’s RenNano® Platform Genetic Engineering Strategy (Source: https://biocytogen.com/antibody-drug-development/rennano）

Biocytogen Responds to Harbour BioMed’s Patent Claims: RenNano® is an Independently Developed Platform with Distinct Innovation and Full Legal Standing